Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
22. November 2022 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
17. Juni 2022 08:00 ET
|
Cyclerion Therapeutics, Inc.
CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing CY6463 clinical studies in CNS...